12/3
04:31 pm
limn
Liminatus Pharma (NASDAQ:LIMN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Liminatus Pharma (NASDAQ:LIMN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/27
02:50 pm
limn
Liminatus Pharma (NASDAQ:LIMN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Liminatus Pharma (NASDAQ:LIMN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/22
02:11 am
limn
Liminatus Pharma (NASDAQ:LIMN) was downgraded by analysts at
Wall Street
High
Report
Liminatus Pharma (NASDAQ:LIMN) was downgraded by analysts at
Wall Street
10/30
10:56 am
limn
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation [Yahoo! Finance]
Neutral
Report
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation [Yahoo! Finance]
10/30
10:04 am
limn
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
Medium
Report
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation